Description: The Society of Actuaries will host two great events for the health actuarial community, bringing together the industry’s leading actuaries, analysts and professionals to network and discuss impacts of the latest marketplace factors and trends.

Description: Gather with members and non-members in the China actuarial community to discuss recent topics and related issues in areas such as macroeconomic sharing, pension, investment, product strategy, and more.

Description: The Supplemental Health, DI & LTC Conference provides a unique opportunity to consider a cross-functional view of supplemental health products, individual disability insurance, and long-term care standalone and combination products.

Description: This study of socioeconomic inequalities in mortality builds on a previous report in which we identified a large and growing gradient in life expectancy between 1982 and 2019 across U.S. counties classified into 10 socioeconomically homogeneous categories. In this report, we seek to identify the particular causes of death contributing to the growing disadvantage in mortality between populations in the least and most affluent deciles as previously defined.

Description: This article suggests actuaries evolve from technical experts to strategic influencers by strengthening their communication skills. It highlights why data alone isn’t enough—actuaries must clearly convey insights, make recommendations, and tailor messages to business audiences. With practical tips and communication shifts, the piece helps actuaries present their work with greater impact. Written by an experienced actuarial leader, it offers real-world relevance for professionals aiming to drive decisions and add strategic value in healthcare and insurance settings.

Description: It's your first full day of productive learning! Start it off right with a delicious breakfast and warm welcome.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This report explores AI bias in insurance and health data, highlighting the ethical role of actuaries and offering cross-disciplinary guidance for fairer decision-making systems.

Description: Read the June 2019 issue of Health Watch, published by the Health Section. Practical information for actuaries, articles impact sections, section activities.

Description: ACA risk adjustment has now been in play for years. The original intent of risk adjustment was to help stabilize the market through measuring risk levels of each issuer. However, the risk adjustment program may have introduced additional uncertainty due to annual market shifts and model changes, making risk adjustment estimation is a difficult task. This article analyzes the results over time, including impacts from market changes and model changes.